GlassScriptPhysician profile
Taylor M Adlam
NPI 1003473851
$6,627.50
in general payments reported to CMS, 2019-2025
26 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $780 · 2022: $1,187 · 2023: $1,106 · 2024: $1,950 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030 · Education: $489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.53 |
| Education | $488.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,239.33 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,104.82 | 2021-2025 | |
| Janssen Biotech, INC. | $891.93 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $828.32 | 2020-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $398.29 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $384.60 | 2021-2023 | Tremfya |
| Incyte Corporation | $336.67 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $330.83 | 2021-2025 | Winlevi, Absorica Ld |
| Amgen INC. | $187.52 | 2023-2024 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $118.23 | 2024-2025 | Sotyktu |
| Pfizer INC. | $104.47 | 2023-2025 | |
| Lilly USA, LLC | $102.35 | 2021-2025 | Ebglyss, Taltz |
| Ucb, INC. | $82.72 | 2022-2024 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $80.66 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $60.26 | 2023-2024 | Cabtreo, Arazlo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $59.76 | 2022-2025 | Adbry |
| Boston Scientific Corporation | $53.82 | 2025 | Ams 700 |
| Kyowa Kirin, INC. | $42.24 | 2023 | Poteligeo |
| Dermavant Sciences, INC. | $40.71 | 2023 | Vtama |
| Kerecis Limited | $38.92 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.98 | 2024 | Spevigo |
| Mayne Pharma Commercial LLC | $29.11 | 2023 | |
| Arcutis Biotherapeutics, INC. | $27.80 | 2024-2025 | Zoryve |
| Biofrontera INC. | $21.25 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Organogenesis INC. | $16.88 | 2021 | |
| Tactile Systems Technology INC | $13.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Adlam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.